ArticleBlood advances2025

Cost-effectiveness of upfront vs delayed allogeneic hematopoietic stem cell transplant for intermediate risk AML.

Abdulrahman Alhajahjeh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.